• Trending
  • Latest
    Sign in Sign up
    • Log In
    • Register
    • Home
    • Discover
    • Experts
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Mashup Score: 2
      Paper: Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts) - 4 year(s) ago

      Oral and Poster Abstracts 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II Biological, Antibody Therapy, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Diseases, Therapies, Immunotherapy, Lymphoid Malignancies, Biological Processes Michael Dickinson, MBBS1, Carmelo Carlo-Stella, MD2, Franck Morschhauser, MD, PhD3*, Krish…

      Source: ash.confex.com
      Categories: Hem/Oncs, Latest Headlines
      Tweet Tweets with this article
      • Profile photo of 	DrOscarLahoud
        DrOscarLahoud

        RT @mike_dickinson1: Wondering about the durability of remissions obtained on #glofitamab? Latest is here: https://t.co/eq9ejvJujy incl. p…

    Oscar Lahoud

    @DrOscarLahoud

    MSKCC Adult BMT specialist treating blood cancers - myeloma, lymphoma, leukemia. @Umich alumnus. @PSG_inside & judo fan. Proud papa/husband. My personal tweets!

    ASCO 2025

    Advertisement

    Advertisement

    MashupMD
    © 2025 - Mashup Media LLC
    • Terms of Use
    • Privacy Policy
    • Cookie Settings